Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Trading Up 0.2% – Here’s What Happened

Shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) shot up 0.2% on Thursday . The company traded as high as $84.66 and last traded at $84.64. Approximately 4,804 shares were traded during mid-day trading, a decline of 27% from the average daily volume of 6,590 shares. The stock had previously closed at $84.44.

Invesco Biotechnology & Genome ETF Price Performance

The company has a market cap of $263.23 million, a P/E ratio of 20.44 and a beta of 0.72. The firm’s 50-day moving average is $82.05 and its two-hundred day moving average is $81.36.

Hedge Funds Weigh In On Invesco Biotechnology & Genome ETF

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Colonial Trust Advisors bought a new stake in shares of Invesco Biotechnology & Genome ETF in the 4th quarter worth about $25,000. Fifth Third Bancorp bought a new position in shares of Invesco Biotechnology & Genome ETF in the 1st quarter valued at about $30,000. Comerica Bank grew its position in Invesco Biotechnology & Genome ETF by 86.2% in the fourth quarter. Comerica Bank now owns 378 shares of the company’s stock worth $31,000 after acquiring an additional 175 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Invesco Biotechnology & Genome ETF by 74.5% in the third quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock worth $40,000 after acquiring an additional 245 shares in the last quarter. Finally, NewEdge Advisors LLC increased its stake in Invesco Biotechnology & Genome ETF by 63.2% during the third quarter. NewEdge Advisors LLC now owns 883 shares of the company’s stock worth $62,000 after acquiring an additional 342 shares during the last quarter.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.